Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Debt (2016 - 2023)

Avalo Therapeutics (AVTX) has disclosed Non-Current Debt for 8 consecutive years, with $10.5 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Non-Current Debt changed N/A year-over-year to $10.5 million, compared with a TTM value of $10.5 million through Mar 2023, changed N/A, and an annual FY2022 reading of $13.5 million, down 58.93% over the prior year.
  • Non-Current Debt was $10.5 million for Q1 2023 at Avalo Therapeutics, down from $13.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $32.8 million in Q4 2021 and bottomed at $10.5 million in Q1 2023.
  • Average Non-Current Debt over 4 years is $16.9 million, with a median of $14.3 million recorded in 2019.
  • The sharpest move saw Non-Current Debt fell 0.68% in 2019, then tumbled 58.93% in 2022.
  • Year by year, Non-Current Debt stood at $14.3 million in 2019, then surged by 130.33% to $32.8 million in 2021, then plummeted by 58.93% to $13.5 million in 2022, then dropped by 22.36% to $10.5 million in 2023.
  • Business Quant data shows Non-Current Debt for AVTX at $10.5 million in Q1 2023, $13.5 million in Q4 2022, and $16.5 million in Q3 2022.